SQUEEZE - Maximising Impact of Prescription Drugs in Rheumatoid Arthritis

SQUEEZE联盟全面讨论了如何使用生物标志物来优化用于类风湿性关节炎（RA）的疾病修饰抗风湿药物（DMARDs）。类风湿性关节炎是一种慢性免疫介导的疾病，对健康相关的生活质量和社会经济影响巨大。临床护理中有多种不同靶点的dmard可供选择，然而，如果没有足够的标记物表明针对特定患者的最佳选择，治疗策略可能无效、繁琐且昂贵。在转化和临床研究方面拥有一流记录的领先学术中心团队，与患者和中小型企业（sme）一起，开始实施一项合作计划，以推进生物标志物的临床应用，以提高已批准的dmard的疗效、安全性和价值。SQUEEZE利用来自数据科学、临床试验、转化科学和行为科学的模型，以一种互补、协同和非重叠的方式解决生物标志物的使用问题，以提高选择最符合患者免疫表型和临床特征的DMARD的能力，优化现有DMARD的剂量和途径；并为注重患者偏好和需求的创新护理模式提供信息，以增加对处方药的依从性。通过9个专门的工作包，SQUEEZE整合了临床、实验室、分子、数字和行为生物标志物，以识别对治疗有高反应可能性的患者，并为个体患者选择最有可能受益的药物；因此，通过与其他欧盟范围内的活动协同作用，（通过最大限度地利用现有药物）提高现有疗法的疗效和安全性。

The SQUEEZE consortium comprehensively addressed how biomarkers can be used to optimize disease modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis (RA). RA is a chronic immune-mediated disease with enormous health-related quality of life and socioeconomic impact. A broad choice of DMARDs with different targets is up to date available in clinical care, however without sufficient markers indicating the best choice for a particular patient, treatment strategies can be ineffective, cumbersome and expensive. The team of leading academic centres with a first-class record in translational and clinical research, together with patients and small and medium sized enterprises (SMEs) has set out to deliver a collaborative programme to advance the clinical application of biomarkers to improve benefit, safety, and value of approved DMARDs. SQUEEZE utilizes models from data science, clinical trials, translational science, and behavioural science to engage in a complementary, synergistic, and non-overlapping manner addressing the use of biomarkers to improve the ability to select the DMARD with the highest likelihood of fitting the immunophenotypic and clinical profile of the patient, to optimise dose and route of existing DMARDs; and to inform an innovative model of care focusing on patient ´s preferences and needs to increase adherence to prescribed drugs. Through nine dedicated work packages SQUEEZE integrates to validate clinical, laboratory, molecular, digital and behavioural biomarkers to enable the recognition of patients with high likelihood of response to treatment and the selection of the drug with highest chance of benefit for an individual patient; and as such improve efficacy and safety of existing therapies (by squeezing the most out of existing drugs) in synergy with other EU-wide activities.